fenofibrate has been researched along with Diabetic Retinopathy in 77 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 9.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| "The purpose of this study is to study the benefit of addition of oral fenofibrate to the current regimen of diabetic macular edema (DME) management and quantify its effect on macular thickness and visual function in DME." | 9.27 | Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. ( Hande, P; Murali, S; Shetty, J; Srinivasan, S, 2018) |
| " The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME." | 9.19 | Effects of fenofibric acid on diabetic macular edema: the MacuFen study. ( Ansquer, JC; Aubonnet, P; MacuFEN Study Investigators, FT; Massin, P; Peto, T, 2014) |
| "Treatment with fenofibrate in individuals with type 2 diabetes mellitus reduces the need for laser treatment for diabetic retinopathy, although the mechanism of this effect does not seem to be related to plasma concentrations of lipids." | 9.12 | Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. ( Colman, PG; Crimet, DC; d'Emden, MC; Davis, TM; Keech, AC; Laatikainen, LT; Merrifield, A; Mitchell, P; Moffitt, MS; O'Connell, RL; O'Day, J; Simes, RJ; Summanen, PA; Taskinen, MR; Tse, D; Williamson, E, 2007) |
| "The drug fenofibrate has received major attention as a novel medical treatment for diabetic retinopathy (DR) and other diabetes-induced microvascular complications." | 8.89 | An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. ( Jenkins, AJ; Keech, AC; Lamoureux, EL; Ma, JX; Noonan, JE; Wang, JJ, 2013) |
| "There are now robust and consistent clinical data to recommend fenofibrate as an adjunctive treatment for early diabetic retinopathy in patients with type 2 diabetes mellitus, taking into account the risks vs benefits of therapy." | 8.88 | Fenofibrate - a potential systemic treatment for diabetic retinopathy? ( Mitchell, P; Simó, R; Wong, TY, 2012) |
| "In this propensity-matched study using the Korean National Health Insurance Service cohort (2002-2019), patients with type 2 diabetes and metabolic syndrome (≥ 30 years) receiving statin therapy were matched 1:2 by propensity score into the statin plus fenofibrate group (n = 22,395) and statin-only group (n = 43,191)." | 8.31 | Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study. ( Choi, J; Kim, NH; Kim, SG; Kim, YH; Lee, H, 2023) |
| "To assess the association between fenofibrate use and the progression from NPDR to VTDR, proliferative DR (PDR), or diabetic macular edema (DME)." | 8.12 | Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy. ( Bavinger, JC; Meer, E; VanderBeek, BL; Yu, Y, 2022) |
| "Human microvascular endothelial cells (HMECs), retinal pericytes (HRPs) and Müller cells (MIO-M1) were cultured in intermittent high glucose (intHG) and/or hypoxia, with addition of fenofibrate or thiamine." | 7.96 | Effects of thiamine and fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier. ( Beltramo, E; Gai, C; Mazzeo, A; Porta, M; Trento, M, 2020) |
| "Numerous studies have reported the efficacy of fenofibrate for patients with diabetic retinopathy (DRP)." | 7.91 | Efficacy of fenofibrate for diabetic retinopathy: A systematic review protocol. ( Han, L; Liu, HW; Qi, YX; Su, XJ, 2019) |
| "To explore the influence of fenofibrate on the diabetic retinopathy (DR) in rats via the sirtuin1 (SIRT1)/nuclear factor-κB (NF-κB) signaling pathway." | 7.91 | Effect of fenofibrate on diabetic retinopathy in rats via SIRT1/NF-κB signaling pathway. ( Chen, N; Jiang, K; Yan, GG, 2019) |
| "Fenofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist and has been shown to have therapeutic effects on diabetic retinopathy (DR)." | 7.91 | Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration. ( Chen, Q; Deng, G; Du, Y; Ma, JX; Ma, X; Matlock, G; Meng, T; Qiu, F; Shao, Y; Wang, X; Wu, W; Xu, Q; Zhou, K, 2019) |
| "The role of cytokines in diabetic retinopathy (DR) and effects of fenofibrate on cytokines were explored by observing changes in serum IL-1β, TNF-α, VEGF, and Lp-PLA2 in different stages of DR and the intervention effect of oral fenofibrate on cytokines." | 7.85 | Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients. ( Cui, T; Ju, HB; Li, LF; Song, J; Wang, S; Zhang, FX; Zhang, HY, 2017) |
| "Diabetic retinopathy is a significant cause of vision impairment, especially affecting those of working age." | 6.52 | The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review. ( Newman, D; Ong, J; Ooi, JL; Sharma, N, 2015) |
| "Two large-scale randomized clinical trials compared fenofibrate and placebo in diabetic patients with pre-existing retinopathy (FIELD study) or risk factors (ACCORD trial) on an intention-to-treat basis and reported a significant reduction in the progression of diabetic retinopathy in the fenofibrate arms." | 5.69 | G-estimation of structural nested mean models for interval-censored data using pseudo-observations. ( Brookhart, MA; Fine, J; Tanaka, S, 2023) |
| "Fenofibrate has received great attention as it benefits diabetic patients by reducing retinal laser requirement." | 5.48 | Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. ( Cheng, R; Li, J; Liu, Q; Ma, JX; Yi, J; Zhang, F; Zhang, X, 2018) |
| "Current, moderate-certainty evidence suggests that in a mixed group of people with and without overt retinopathy, who live with T2D, fenofibrate likely results in little to no difference in progression of diabetic retinopathy." | 5.41 | Fenofibrate for diabetic retinopathy. ( Inoue, K; Kataoka, SY; Kataoka, Y; Kawano, S; Lois, N; Watanabe, N, 2023) |
| "The purpose of this study is to study the benefit of addition of oral fenofibrate to the current regimen of diabetic macular edema (DME) management and quantify its effect on macular thickness and visual function in DME." | 5.27 | Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. ( Hande, P; Murali, S; Shetty, J; Srinivasan, S, 2018) |
| " 140 mmHg), and dyslipidemia (fenofibrate [160 mg] plus simvastatin or placebo plus simvastatin)." | 5.22 | Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. ( , 2016) |
| " The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME." | 5.19 | Effects of fenofibric acid on diabetic macular edema: the MacuFen study. ( Ansquer, JC; Aubonnet, P; MacuFEN Study Investigators, FT; Massin, P; Peto, T, 2014) |
| "5% with fenofibrate for intensive dyslipidemia therapy, versus 10." | 5.14 | Effects of medical therapies on retinopathy progression in type 2 diabetes. ( Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U, 2010) |
| "Treatment with fenofibrate in individuals with type 2 diabetes mellitus reduces the need for laser treatment for diabetic retinopathy, although the mechanism of this effect does not seem to be related to plasma concentrations of lipids." | 5.12 | Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. ( Colman, PG; Crimet, DC; d'Emden, MC; Davis, TM; Keech, AC; Laatikainen, LT; Merrifield, A; Mitchell, P; Moffitt, MS; O'Connell, RL; O'Day, J; Simes, RJ; Summanen, PA; Taskinen, MR; Tse, D; Williamson, E, 2007) |
| " Fenofibrate significantly slowed the progression of early diabetic retinopathy by 30 to 40% within 4 to 5 years in patients with type 2 diabetes mellitus and pre-existing retinopathy at baseline." | 4.93 | Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review. ( Czupryniak, L; Gogtay, JA; Joshi, SR; Lopez, M, 2016) |
| "The drug fenofibrate has received major attention as a novel medical treatment for diabetic retinopathy (DR) and other diabetes-induced microvascular complications." | 4.89 | An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. ( Jenkins, AJ; Keech, AC; Lamoureux, EL; Ma, JX; Noonan, JE; Wang, JJ, 2013) |
| "There are now robust and consistent clinical data to recommend fenofibrate as an adjunctive treatment for early diabetic retinopathy in patients with type 2 diabetes mellitus, taking into account the risks vs benefits of therapy." | 4.88 | Fenofibrate - a potential systemic treatment for diabetic retinopathy? ( Mitchell, P; Simó, R; Wong, TY, 2012) |
| "In this propensity-matched study using the Korean National Health Insurance Service cohort (2002-2019), patients with type 2 diabetes and metabolic syndrome (≥ 30 years) receiving statin therapy were matched 1:2 by propensity score into the statin plus fenofibrate group (n = 22,395) and statin-only group (n = 43,191)." | 4.31 | Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study. ( Choi, J; Kim, NH; Kim, SG; Kim, YH; Lee, H, 2023) |
| "In 6002 Australian adults with type 2 diabetes and a median 5-year follow-up in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial, baseline socioeconomic status (SES) and self-reported education level were not related to development of on-trial sight-threatening diabetic retinopathy." | 4.31 | No relationship between socioeconomic status, education level and development and progression of diabetic retinopathy in type 2 diabetes: a FIELD trial substudy. ( Aryal, N; Brazionis, L; Colman, PG; Januszewski, AS; Jenkins, AJ; Keech, AC; Mitchell, P; O'Connell, R; O'Day, J; Rao, B; Shimmin, G, 2023) |
| "To assess the association between fenofibrate use and the progression from NPDR to VTDR, proliferative DR (PDR), or diabetic macular edema (DME)." | 4.12 | Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy. ( Bavinger, JC; Meer, E; VanderBeek, BL; Yu, Y, 2022) |
| "Human microvascular endothelial cells (HMECs), retinal pericytes (HRPs) and Müller cells (MIO-M1) were cultured in intermittent high glucose (intHG) and/or hypoxia, with addition of fenofibrate or thiamine." | 3.96 | Effects of thiamine and fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier. ( Beltramo, E; Gai, C; Mazzeo, A; Porta, M; Trento, M, 2020) |
| "Numerous studies have reported the efficacy of fenofibrate for patients with diabetic retinopathy (DRP)." | 3.91 | Efficacy of fenofibrate for diabetic retinopathy: A systematic review protocol. ( Han, L; Liu, HW; Qi, YX; Su, XJ, 2019) |
| "Fenofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist and has been shown to have therapeutic effects on diabetic retinopathy (DR)." | 3.91 | Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration. ( Chen, Q; Deng, G; Du, Y; Ma, JX; Ma, X; Matlock, G; Meng, T; Qiu, F; Shao, Y; Wang, X; Wu, W; Xu, Q; Zhou, K, 2019) |
| "Previous studies suggested that use of fenofibrate could significantly reduce the rate of progression into diabetic retinopathy (DR), and that retinal nerve fiber layer (RNFL) loss, which has been considered an important indicator for retinal neurodegeneration, might precede microvascular changes." | 3.88 | The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study. ( Qi, Y; Shi, R; Zhao, L, 2018) |
| "The role of cytokines in diabetic retinopathy (DR) and effects of fenofibrate on cytokines were explored by observing changes in serum IL-1β, TNF-α, VEGF, and Lp-PLA2 in different stages of DR and the intervention effect of oral fenofibrate on cytokines." | 3.85 | Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients. ( Cui, T; Ju, HB; Li, LF; Song, J; Wang, S; Zhang, FX; Zhang, HY, 2017) |
| "There is clinical evidence that fenofibrate, a PPARα agonist, arrests the progression of diabetic macular edema (DME)." | 3.83 | Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-κB activity. ( Garcia-Ramírez, M; Hernández, C; Palomer, X; Simó, R; Vázquez-Carrera, M, 2016) |
| "There is now consistent evidence from two major clinical trials (the Fenofibrate Intervention and Event Lowering in Diabetes and the Action to Control Cardiovascular Risk in Diabetes Eye) that fenofibrate arrests the progression of diabetic retinopathy in type 2 diabetic patients." | 3.81 | Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. ( Bogdanov, P; Carvalho, AR; Corraliza, L; Hernández, C; Simó, R, 2015) |
| "Diabetic retinopathy is a significant cause of vision impairment, especially affecting those of working age." | 2.52 | The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review. ( Newman, D; Ong, J; Ooi, JL; Sharma, N, 2015) |
| "Diabetic retinopathy was associated with ∼ 1." | 2.47 | Does microvascular disease predict macrovascular events in type 2 diabetes? ( Dodson, PM; Fioretto, P; Rosenson, RS, 2011) |
| "Fenofibrate has received great attention as it benefits diabetic patients by reducing retinal laser requirement." | 1.48 | Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation. ( Cheng, R; Li, J; Liu, Q; Ma, JX; Yi, J; Zhang, F; Zhang, X, 2018) |
| " Dynamic observation of certain ophthalmologic (visual acuity, macular thickness zone) and system functional parameters (lipid fractions content in serum) in long-term use of this medical drug in 20 patients with diabetes type 2 and DMO for 8 months." | 1.46 | [CHANGES OF LIFETIME MORPHOLOGICAL PARAMETERS OF THE RETINA ON THE BACKGROUND OF CORRECTION OF LIPID METABOLISM IN PATIENTSWITH TYPE 2 DIABETES MELLITUS]. ( Veselovskaya, NN, 2017) |
| "Fenofibrate treatment abrogated these changes." | 1.42 | Fenofibrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway. ( Gu, Q; Li, J; Li, T; Wang, N; Xu, X; Zhao, S; Zheng, B; Zheng, Z, 2015) |
| "Fenofibrate is a lipid-lowering agent that has been shown to be capable of preventing DR progression." | 1.40 | Effects of fenofibrate on adiponectin expression in retinas of streptozotocin-induced diabetic rats. ( Hsu, YJ; Wang, LC; Yang, CH; Yang, CM; Yang, WS, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.30) | 18.2507 |
| 2000's | 12 (15.58) | 29.6817 |
| 2010's | 52 (67.53) | 24.3611 |
| 2020's | 12 (15.58) | 2.80 |
| Authors | Studies |
|---|---|
| Preiss, D | 1 |
| Spata, E | 1 |
| Holman, RR | 1 |
| Coleman, RL | 1 |
| Lovato, L | 1 |
| Ginsberg, HN | 2 |
| Armitage, J | 1 |
| Rao, BN | 1 |
| Quinn, N | 2 |
| Januszewski, AS | 3 |
| Peto, T | 2 |
| Brazionis, L | 3 |
| Aryal, N | 3 |
| O'Connell, RL | 2 |
| Li, L | 1 |
| Summanen, P | 1 |
| Scott, R | 2 |
| O'Day, J | 4 |
| Keech, AC | 7 |
| Jenkins, AJ | 6 |
| Meer, E | 1 |
| Bavinger, JC | 1 |
| Yu, Y | 1 |
| VanderBeek, BL | 1 |
| Frank, RN | 2 |
| O'Connell, R | 2 |
| Mitchell, P | 7 |
| Kim, NH | 1 |
| Choi, J | 1 |
| Kim, YH | 1 |
| Lee, H | 1 |
| Kim, SG | 1 |
| Dong, L | 1 |
| Cheng, R | 4 |
| Ma, X | 2 |
| Liang, W | 1 |
| Hong, Y | 1 |
| Li, H | 1 |
| Zhou, K | 3 |
| Du, Y | 2 |
| Takahashi, Y | 2 |
| Zhang, X | 2 |
| Li, XR | 1 |
| Ma, JX | 7 |
| Kataoka, SY | 1 |
| Lois, N | 1 |
| Kawano, S | 1 |
| Kataoka, Y | 1 |
| Inoue, K | 1 |
| Watanabe, N | 1 |
| Tanaka, S | 1 |
| Brookhart, MA | 1 |
| Fine, J | 1 |
| Rao, B | 1 |
| Shimmin, G | 1 |
| Colman, PG | 2 |
| Chen, N | 1 |
| Jiang, K | 1 |
| Yan, GG | 1 |
| Mazzeo, A | 1 |
| Gai, C | 1 |
| Trento, M | 1 |
| Porta, M | 1 |
| Beltramo, E | 1 |
| Lin, YC | 1 |
| Chen, YC | 1 |
| Horng, JT | 1 |
| Chen, JM | 1 |
| Ju, HB | 1 |
| Zhang, FX | 1 |
| Wang, S | 1 |
| Song, J | 1 |
| Cui, T | 1 |
| Li, LF | 1 |
| Zhang, HY | 1 |
| Liu, Q | 1 |
| Zhang, F | 1 |
| Yi, J | 1 |
| Li, J | 3 |
| Srinivasan, S | 1 |
| Hande, P | 1 |
| Shetty, J | 1 |
| Murali, S | 1 |
| Shi, R | 1 |
| Zhao, L | 1 |
| Qi, Y | 1 |
| Veselovskaya, NN | 1 |
| Wang, P | 1 |
| Chen, Z | 1 |
| Yu, S | 1 |
| Xu, H | 1 |
| Pearsall, EA | 1 |
| Matsuzaki, S | 1 |
| Ding, L | 2 |
| Ahn, B | 1 |
| Kinter, M | 1 |
| Humphries, KM | 2 |
| Quiambao, AB | 1 |
| Farjo, RA | 1 |
| Qiu, F | 1 |
| Meng, T | 1 |
| Chen, Q | 1 |
| Shao, Y | 1 |
| Matlock, G | 1 |
| Wu, W | 1 |
| Wang, X | 1 |
| Deng, G | 1 |
| Xu, Q | 1 |
| Su, XJ | 1 |
| Han, L | 1 |
| Qi, YX | 1 |
| Liu, HW | 1 |
| Kalra, S | 1 |
| Sahay, R | 1 |
| Simó, R | 12 |
| Roy, S | 3 |
| Behar-Cohen, F | 1 |
| Keech, A | 1 |
| Wong, TY | 6 |
| Noonan, JE | 1 |
| Wang, JJ | 3 |
| Lamoureux, EL | 1 |
| Bogdanov, P | 1 |
| Hernández, C | 9 |
| Corraliza, L | 2 |
| Carvalho, AR | 1 |
| Hu, Y | 2 |
| Gu, X | 1 |
| Elliott, MH | 1 |
| Xia, X | 1 |
| Massin, P | 1 |
| Ansquer, JC | 1 |
| Aubonnet, P | 1 |
| MacuFEN Study Investigators, FT | 1 |
| Chew, EY | 3 |
| Davis, MD | 2 |
| Danis, RP | 2 |
| Lovato, JF | 2 |
| Perdue, LH | 2 |
| Greven, C | 1 |
| Genuth, S | 2 |
| Goff, DC | 2 |
| Leiter, LA | 1 |
| Ismail-Beigi, F | 1 |
| Ambrosius, WT | 2 |
| Zhang, C | 1 |
| Wang, H | 1 |
| Nie, J | 1 |
| Wang, F | 1 |
| Hsu, YJ | 1 |
| Wang, LC | 1 |
| Yang, WS | 1 |
| Yang, CM | 1 |
| Yang, CH | 1 |
| Garcia-Ramírez, M | 3 |
| Palomer, X | 1 |
| Vázquez-Carrera, M | 1 |
| Ballarini, S | 1 |
| Cunha-Vaz, J | 1 |
| Ji, L | 1 |
| Haller, H | 1 |
| Zimmet, P | 2 |
| Sharma, N | 1 |
| Ooi, JL | 1 |
| Ong, J | 1 |
| Newman, D | 1 |
| Zhao, S | 1 |
| Wang, N | 1 |
| Zheng, B | 1 |
| Li, T | 1 |
| Gu, Q | 1 |
| Xu, X | 1 |
| Zheng, Z | 1 |
| Kim, D | 1 |
| Modjtahedi, BS | 1 |
| Bose, N | 1 |
| Papakostas, TD | 1 |
| Morse, L | 1 |
| Vavvas, DG | 1 |
| Kishan, AU | 1 |
| Czupryniak, L | 1 |
| Joshi, SR | 1 |
| Gogtay, JA | 1 |
| Lopez, M | 1 |
| de Moraes, G | 1 |
| Layton, CJ | 1 |
| Pelletier, AL | 1 |
| Rojas-Roldan, L | 1 |
| Coffin, J | 1 |
| Knickelbein, JE | 1 |
| Abbott, AB | 1 |
| Liu, WY | 1 |
| Tzeng, TF | 1 |
| Liu, IM | 1 |
| Farris, RA | 1 |
| Price, ET | 1 |
| Dodson, PM | 4 |
| Steiner, G | 1 |
| Klein, BE | 1 |
| Gangaputra, S | 1 |
| Greven, CM | 1 |
| Hubbard, L | 1 |
| Esser, BA | 1 |
| Cushman, WC | 1 |
| Elam, MB | 1 |
| Gerstein, HC | 1 |
| Schubart, U | 1 |
| Fine, LJ | 1 |
| Lim, LS | 2 |
| Liew, G | 3 |
| Cheung, N | 2 |
| Giral, P | 1 |
| Rosenbaum, D | 1 |
| Baum, SJ | 1 |
| Villarroel, M | 1 |
| Wright, AD | 1 |
| Egan, A | 1 |
| Byrne, M | 1 |
| Hermans, MP | 1 |
| Ai, M | 1 |
| Yoshida, M | 1 |
| Rosenson, RS | 1 |
| Fioretto, P | 1 |
| Miranda, S | 1 |
| González-Rodríguez, Á | 1 |
| Revuelta-Cervantes, J | 1 |
| Valverde, ÁM | 1 |
| Treacy, MP | 1 |
| Hurst, TP | 1 |
| Chen, Y | 1 |
| Lin, M | 1 |
| Mott, R | 1 |
| Lyons, TJ | 1 |
| Abcouwer, SF | 1 |
| Summanen, PA | 1 |
| Davis, TM | 1 |
| Moffitt, MS | 1 |
| Taskinen, MR | 1 |
| Simes, RJ | 1 |
| Tse, D | 1 |
| Williamson, E | 1 |
| Merrifield, A | 1 |
| Laatikainen, LT | 1 |
| d'Emden, MC | 1 |
| Crimet, DC | 1 |
| Gillies, M | 1 |
| Firth, J | 1 |
| Zhou, JY | 1 |
| Zhou, SW | 1 |
| Rencová, E | 1 |
| Novák, J | 1 |
| Saic, E | 1 |
| Kalinová, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume: Assessments on Retinal Endothelial Vascular Dysfunction, Inflammation, and Angiogenesis in Diabetic Retinopathy With Dyslipidemia[NCT04885153] | 36 participants (Actual) | Interventional | 2016-11-01 | Completed | |||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study[NCT00542178] | Phase 3 | 3,472 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients[NCT06155331] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 547 |
| Standard Glycemia Control | 623 |
| Intensive Blood Pressure Control | 266 |
| Standard Blood Pressure Control | 300 |
| Fenofibrate + Simvastatin Therapy | 305 |
| Placebo + Simvastatin Therapy | 299 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 44 |
| Standard Glycemia Control | 40 |
| Intensive Blood Pressure Control | 18 |
| Standard Blood Pressure Control | 20 |
| Fenofibrate + Simvastatin Therapy | 24 |
| Placebo + Simvastatin Therapy | 22 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 744 |
| Standard Glycemia Control | 752 |
| Intensive Blood Pressure Control | 367 |
| Standard Blood Pressure Control | 382 |
| Fenofibrate + Simvastatin Therapy | 354 |
| Placebo + Simvastatin Therapy | 393 |
Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher. (NCT00542178)
Timeframe: Measured at Year 4
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemia Control | 104 |
| Standard Glycemia Control | 149 |
| Intensive Blood Pressure Control | 67 |
| Standard Blood Pressure Control | 54 |
| Fenofibrate + Simvastatin Therapy | 52 |
| Placebo + Simvastatin Therapy | 80 |
20 reviews available for fenofibrate and Diabetic Retinopathy
| Article | Year |
|---|---|
Fenofibrate for diabetic retinopathy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Mac | 2023 |
Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; | 2013 |
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes.
Topics: Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipidemic Agents; Microvessels; | 2013 |
Protective factors in diabetic retinopathy: focus on blood-retinal barrier.
Topics: Animals; Blood-Retinal Barrier; Diabetic Retinopathy; Erythropoietin; Fenofibrate; Humans; Insulin-L | 2014 |
Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review.
Topics: Animals; Calcium Dobesilate; Diabetic Retinopathy; Fenofibrate; Humans; Renin-Angiotensin System | 2015 |
The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review.
Topics: Australia; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans | 2015 |
Lipids and Diabetic Retinopathy.
Topics: Diabetic Retinopathy; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipi | 2016 |
Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Disease Progression; Drug C | 2016 |
Therapeutic targeting of diabetic retinal neuropathy as a strategy in preventing diabetic retinopathy.
Topics: Animals; Color Vision Defects; Contrast Sensitivity; Dark Adaptation; Diabetic Neuropathies; Diabeti | 2016 |
Vision Loss in Older Adults.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antihypertensive Agents; Ascorbic Acid; Bevacizuma | 2016 |
Fenofibrate and Diabetic Retinopathy.
Topics: Diabetic Retinopathy; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi | 2016 |
Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?
Topics: Diabetic Retinopathy; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi | 2009 |
Advances in the medical treatment of diabetic retinopathy.
Topics: Blindness; Blood-Retinal Barrier; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Dia | 2009 |
How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Topics: Albuminuria; Amputation, Surgical; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2009 |
Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.
Topics: Adult; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Glycate | 2011 |
Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.
Topics: Albuminuria; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Evidence-Based Medicine; Fenofibrate; | 2011 |
Does microvascular disease predict macrovascular events in type 2 diabetes?
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Do | 2011 |
Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate.
Topics: Blood Glucose; Blood Pressure; Diabetic Retinopathy; Fenofibrate; Humans; Hypolipidemic Agents; Rand | 2012 |
Fenofibrate - a potential systemic treatment for diabetic retinopathy?
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipid | 2012 |
The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy.
Topics: Diabetic Retinopathy; Eye; Fenofibrate; Humans; Hypolipidemic Agents; Injections; PPAR alpha; Treatm | 2012 |
9 trials available for fenofibrate and Diabetic Retinopathy
| Article | Year |
|---|---|
G-estimation of structural nested mean models for interval-censored data using pseudo-observations.
Topics: Causality; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans | 2023 |
Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema.
Topics: Aged; Diabetic Retinopathy; Disease Progression; Dose-Response Relationship, Drug; Female; Fenofibra | 2018 |
Effects of fenofibric acid on diabetic macular edema: the MacuFen study.
Topics: Anticholesteremic Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Fema | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Topics: Aged; Cardiovascular Diseases; Cataract Extraction; Diabetes Mellitus, Type 2; Diabetic Retinopathy; | 2014 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Re | 2016 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
[Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Humans; Hypolipidemic Ag | 2010 |
Fenofibrate for diabetic retinopathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Follow-Up Studies; Humans; Hypolipidem | 2007 |
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Humans; Hypolipidemic Ag | 2007 |
48 other studies available for fenofibrate and Diabetic Retinopathy
| Article | Year |
|---|---|
Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Diabetes Mellitus; Diabetic Retinopathy; Fenofibrate; Humans; Hypolipidemic Agents; Lasers; Randomiz | 2022 |
Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Glycated Hemoglobin; Humans; Male; Ris | 2022 |
Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Humans; | 2022 |
Use of Fenofibrate in the Management of Diabetic Retinopathy-Large Population Analyses.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans | 2022 |
Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Retinal Vessels; Venules | 2022 |
Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensity-matched cohort study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Hydroxymethylg | 2023 |
Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Monocytes; Nucleotidyltransfe | 2023 |
No relationship between socioeconomic status, education level and development and progression of diabetic retinopathy in type 2 diabetes: a FIELD trial substudy.
Topics: Adult; Australia; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Educational Status; Fenofibrate; | 2023 |
Effect of fenofibrate on diabetic retinopathy in rats via SIRT1/NF-κB signaling pathway.
Topics: Animals; Diabetic Retinopathy; Fenofibrate; Hypolipidemic Agents; Injections, Intraperitoneal; NF-ka | 2019 |
Effects of thiamine and fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier.
Topics: Blood-Retinal Barrier; Cell Hypoxia; Cells, Cultured; Diabetic Retinopathy; Dose-Response Relationsh | 2020 |
Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fem | 2020 |
Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Blood Glucose; Cytokines; Diabetes Mellitus, Ty | 2017 |
Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation.
Topics: Animals; Capillary Permeability; Caspase 1; Diabetes Mellitus, Experimental; Diabetic Retinopathy; F | 2018 |
The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibr | 2018 |
[CHANGES OF LIFETIME MORPHOLOGICAL PARAMETERS OF THE RETINA ON THE BACKGROUND OF CORRECTION OF LIPID METABOLISM IN PATIENTSWITH TYPE 2 DIABETES MELLITUS].
Topics: Aged; Biguanides; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; | 2017 |
Fenofibrate Ameliorates Oxidative Stress-Induced Retinal Microvascular Dysfunction in Diabetic Rats.
Topics: Animals; Carrier Proteins; Cell Cycle Proteins; Diabetes Mellitus, Experimental; Diabetic Retinopath | 2018 |
Neuroprotective effects of PPARα in retinopathy of type 1 diabetes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Disease Models, Animal; Fenofib | 2019 |
Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Topics: Animals; Capillary Permeability; Choroidal Neovascularization; Diabetes Mellitus, Experimental; Diab | 2019 |
Efficacy of fenofibrate for diabetic retinopathy: A systematic review protocol.
Topics: Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipidemic Agents; Macular Edema; | 2019 |
Improving Diabetic Retinopathy Outcomes: FIELD Fenofibrate.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Hypolipidemic Agents; Lipids | 2018 |
Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Models, Animal; Excitat | 2015 |
Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina.
Topics: Animals; Apoptosis; Capillaries; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabeti | 2014 |
Systemic therapies for diabetic retinopathy: the accord eye study.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fenofibrate; Human | 2014 |
Effects of fenofibrate on adiponectin expression in retinas of streptozotocin-induced diabetic rats.
Topics: Adiponectin; Animals; Anti-Inflammatory Agents; Aqueous Humor; Blood Glucose; Cell Line; Diabetes Me | 2014 |
Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-κB activity.
Topics: Blood-Retinal Barrier; Capillary Permeability; Cells, Cultured; Cytokines; Diabetic Retinopathy; Dow | 2016 |
Fenofibrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway.
Topics: Cells, Cultured; Diabetic Retinopathy; Endothelial Cells; Fenofibrate; Glucose; Humans; NF-kappa B; | 2015 |
Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy.
Topics: Animals; Anticholesteremic Agents; Blotting, Western; Capillary Permeability; Cells, Cultured; Colla | 2015 |
Zerumbone, a Bioactive Sesquiterpene, Ameliorates Diabetes-Induced Retinal Microvascular Damage through Inhibition of Phospho-p38 Mitogen-Activated Protein Kinase and Nuclear Factor-κB Pathways.
Topics: Animals; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Fenofibrate; | 2016 |
Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes-Associated Retinopathy.
Topics: ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Biomark | 2017 |
[Fenofibrate in the treatment of diabetic retinopathy].
Topics: Diabetic Retinopathy; Fenofibrate; Humans; Hypolipidemic Agents | 2008 |
Preventing diabetic complications: a primary care perspective.
Topics: Cost of Illness; Diabetes Complications; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neu | 2009 |
Reduction in risk of progression of diabetic retinopathy.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug | 2010 |
Mixed messages on systemic therapies for diabetic retinopathy.
Topics: Blood Glucose; Blood Pressure; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypol | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: 2,3-Diphosphoglycerate; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofi | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypertens | 2010 |
Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.
Topics: Aged; AMP-Activated Protein Kinases; Biological Transport; Blood-Retinal Barrier; Cell Line; Cell Me | 2011 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypolipid | 2011 |
Fibrate use in the United States and Canada.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Drug Utilization; Dyslipid | 2011 |
Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions.
Topics: Aged; Apoptosis; Autophagy; bcl-X Protein; Biomarkers; Blood Glucose; Blood-Retinal Barrier; Case-Co | 2012 |
Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models.
Topics: Animals; Capillary Permeability; Cell Adhesion; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Dis | 2013 |
Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Fenofibrate; Hypoglycemic Agents; Male; PP | 2013 |
Diabetic retinopathy: treatment and prevention.
Topics: Combined Modality Therapy; Diabetic Retinopathy; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic A | 2007 |
Fenofibrate and diabetic retinopathy.
Topics: Diabetic Retinopathy; Fenofibrate; Humans; Hypolipidemic Agents; Laser Therapy; Microcirculation | 2008 |
Fenofibrate and diabetic retinopathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fenofibrate; Humans; Hypolipidemic Agents | 2008 |
Fenofibrate and diabetic retinopathy.
Topics: Diabetic Retinopathy; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipid | 2008 |
Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy | 2007 |
[Objective evaluation of the success of treatment in exudative diabetic maculopathy].
Topics: Aged; Combined Modality Therapy; Diabetic Retinopathy; Exudates and Transudates; Female; Fenofibrate | 1992 |